Search Results for 'bone therapeutics'
-
Biologics | Large Joint
Bone Therapeutics Gains Approval to Trial OA Knee Pain Therapies
Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain, ALLOB Phase IIb study in difficult fractures.Bone Therapeutics 03.25.20
-
Biologics
Global Bone Graft and Substitutes Market to Reach $4.67B by 2027
Adoption of inorganic growth strategies, increase in road accidents and injuries is expected to boost growth.Business Wire 02.07.20
-
Biologics
Bone Therapeutics Appoints New Chairman
Jean Stéphenne brings extensive biotech and pharma experience to the the bone cell therapy company.GlobeNewswire 02.21.18
-
Bone Therapeutics Appoints Chief Financial Officer
New hire has extensive international finance experience at major public and privately-owned companies.Bone Therapeutics 09.01.17
-
Biologics
Bone Therapeutics Completes Recruitment in Spinal Fusion Study
Company is also extending trial to assess early onset of bone formation and fusion.Bone Therapeutics SA 05.03.16
-
Bone Therapeutics Reports Initial Efficacy Results from Osteoblastic Cell Product Trial
Product treats severe osteoporosis.Bone Therapeutics Inc. 03.31.16
-
Biologics
Bone Therapeutics Bullish on Primary Trial Results of Cell-Based, Bone-Forming Product
Trial is evaluating safety and efficacy of Allob product to treat delayed-union fractures of long bones.01.21.15
-
Bone Therapeutics Authorized to Enroll Patients in U.K. Clinical Trial
Five British centers approved to test regenerative therapy.12.09.14
-
Bone Therapeutics and Kasios Form Product Development Partnership
Bone Therapeutics also appoints chief clinical/regulatory officer.11.24.14
-
Bone Therapeutics and Kasios Collaborate on Spinal Fusion Product
Joint effort to combine Bone Therapeutics' cell therapy product with synthetic bone substitute.11.17.14
-
Research & Development
Bone Therapeutics Awarded $5.2 Million Research Grant
Company tapped to help develop technology platform of bio-mimetic and bioactive materials.02.20.14
-
Bone Therapeutics Receives Clearance for Allob Phase I/IIa Trial
Product designed to treat delayed union fractures.10.17.13
-
Bone Therapeutics Hires CFO
New executive has more than 25 years of international business experience.10.10.13
